advertisement
Chen LJ 24
Showing records 1 to 24 | Display all abstracts from Chen LJ108104 Cost-effectiveness analysis of myopia management: A systematic review
Agyekum S
Frontiers in public health 2023; 11: 1093836
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Yousaf K
Genes 2023; 14:
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Lin TY
Ophthalmology and therapy 2023; 12: 1127-1140
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Naz S
Genes 2023; 14:
108104 Cost-effectiveness analysis of myopia management: A systematic review
Chan PP
Frontiers in public health 2023; 11: 1093836
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Hsieh YT
Ophthalmology and therapy 2023; 12: 1127-1140
108104 Cost-effectiveness analysis of myopia management: A systematic review
Zhang Y
Frontiers in public health 2023; 11: 1093836
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Garg SJ
Ophthalmology and therapy 2023; 12: 1127-1140
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Mushtaq A
Genes 2023; 14:
108104 Cost-effectiveness analysis of myopia management: A systematic review
Huo Z
Frontiers in public health 2023; 11: 1093836
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Chen LJ
Ophthalmology and therapy 2023; 12: 1127-1140
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Wohler E; Sobreira N
Genes 2023; 14:
108104 Cost-effectiveness analysis of myopia management: A systematic review
Yip BHK
Frontiers in public health 2023; 11: 1093836
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Chen KJ
Ophthalmology and therapy 2023; 12: 1127-1140
108104 Cost-effectiveness analysis of myopia management: A systematic review
Ip P
Frontiers in public health 2023; 11: 1093836
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Ho BM
Genes 2023; 14:
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Wu WC; Lai CC
Ophthalmology and therapy 2023; 12: 1127-1140
108104 Cost-effectiveness analysis of myopia management: A systematic review
Tham CC
Frontiers in public health 2023; 11: 1093836
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Chen LJ; Chu WK
Genes 2023; 14:
108104 Cost-effectiveness analysis of myopia management: A systematic review
Chen LJ
Frontiers in public health 2023; 11: 1093836
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Hwang YS
Ophthalmology and therapy 2023; 12: 1127-1140
107890 Exome Sequencing Reveals Variant Underlying Congenital Hereditary Endothelial Dystrophy (CHED2) Misdiagnosed as Congenital Glaucoma
Bashir R
Genes 2023; 14:
107666 Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor
Kang EY
Ophthalmology and therapy 2023; 12: 1127-1140
108104 Cost-effectiveness analysis of myopia management: A systematic review
Zhang XJ; Pang CP; Yam JC
Frontiers in public health 2023; 11: 1093836
